Regulatory Expansion ACT clinical trial progress for female stress urinary incontinence presents an opportunity to engage with surgeons and healthcare providers seeking new solutions beyond the US market for ProACT, potentially expanding into international markets through partnerships or distributors.

Minimally Invasive Advantage You can position Uromedica’s implantable, adjustable, and removable balloon therapy as a simple, office-visit friendly solution with short procedure times, appealing to clinics aiming to expand non-invasive options for SUI and reduce patient downtime.

Clinical Evidence Leverage the established safety and efficacy profile across over 16,000 patients to support outreach to urology and gynecology practices, hospital systems, and ambulatory surgery centers seeking proven devices with favorable post-operative adjustability.

Growth Financing With modest revenue and recent funding, explore co-development, research collaborations, or strategic partnerships with larger device companies to accelerate scale, distribution, and potential co-marketing opportunities.

Strategic Partnerships Target large medical device players and distributors listed in the market landscape (e.g., Coloplast, Stryker, Medtronic) for potential distribution agreements, white-label opportunities, or clinical collaboration to accelerate market entry and competitive positioning.